OXB Launches Fast-Track Offering to Accelerate Viral Vector Development and Manufacture

OXB is launching what it describes as a fast-track development and manufacturing offering in response to growing customer demand. Specifically, this service will be for clients utilizing lentiviral (LV) and adeno-associated viral (AAV) vectors.

For these clients, OXB, a cell and gene therapy-focused CDMO, will provide expedited routes to good manufacturing practice (GMP) manufacture.

OXB Proprietary Platforms in Focus

The fast-track offering makes use of two proprietary OXB platforms, named inAAVate and LentiVector. OXB says these help provide cost-effective and accelerated options for biotechnology companies with eligible programs.

The goal is giving OXB clients a competitive edge leading to earlier clinical and regulatory milestones—and faster patient access.

OXB Chief Business Officer Sébastien Ribault, PhD, suggests this could cut development timelines in cell and gene therapies by 50%.

How Fast is Fast-Track?

The industry standard pathway to GMP manufacture is approximately 15 months. OXB argues that its fast-track program can shorten this to as little as seven months.

In lentiviral vectors, OXB says the offering can cut timelines from a 12–18-month norm to just nine months. This process utilizes platform datasets and advanced analytics.

“Viral vector development and manufacture represents a frequent bottleneck to clinical readiness,” Ribault said. “Issues can delay critical clinical milestones. The launch of our fast-track offering will make our proprietary platforms accessible to a wider range of clients.”

OXB says its program is particularly suitable for wild type AAVs. It is a high-performance, plug-and-play platform; this reduces need for a number of development steps. At the same time, it achieves high titers, plus more consistent performance at relevant scales of development.

Additional efficiencies, according to OXB, are achieved through integration of vector design, production, purification, and fill-finish.